Clinical trials: Recurrent Colorectal Carcinoma
Colorectal Cancer
A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)
The purpose of this study was to determine the activity of two doses of robatumumab (SCH 717454, MK-7454) in participants with relapsed or recurrent colorectal cancer.
- Trial name
- NCT00551213
- Testing
- Robatumumab, Irinotecan, Cetuximab
- Volunteers
- 67 people
- Sponsor
- Merck Sharp & Dohme LLC
Squamous Cell Carcinoma of the Anal Canal
Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).
This study is a Phase 3 global, multicenter, placebo-controlled double-blind randomized study that will enroll participants with inoperable locally recurrent or metastatic SCAC not previously treated with systemic chemotherapy.
- Trial name
- NCT04472429
- Testing
- carboplatin, paclitaxel, retifanlimab
- Where
- 84 sites in United States, Australia and 11 more
- Volunteers
- 308 people
- Sponsor
- Incyte Corporation
Colorectal Cancer
Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00006046
- Testing
- monoclonal antibody hu3S193
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Ludwig Institute for Cancer Research
Melanoma, Merkel Cell Carcinoma
REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies
Patients received intratumoral (IT) injections of NKTR-262 in 3-week cycles for up to 3 cycles; bempegaldesleukin with or without nivolumab was administered every 3 weeks (q3w), and treatment continued until unacceptable…
- Conditions
- Melanoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- REVEAL (NCT03435640)
- Testing
- NKTR-262, bempegaldesleukin, nivolumab
- Where
- 14 sites in United States
- Volunteers
- 64 people
- Sponsor
- Nektar Therapeutics
Advanced Colorectal Carcinoma, Metastatic Colon Adenocarcinoma
TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study
This phase II trial studies how well TAS-102, irinotecan, and bevacizumab work in treating patients with pre-treated colorectal cancer that has spread to other places in the body (metastatic) or cannot be removed by surgery…
- Conditions
- Advanced Colorectal Carcinoma, Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Recurrent Colon Adenocarcinoma
- Trial name
- NCT04109924
- Testing
- Irinotecan, Bevacizumab, Trifluridine and Tipiracil Hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 42 people
- Sponsor
- Roswell Park Cancer Institute
Adenocarcinoma of the Rectum, Mucinous Adenocarcinoma of the Colon
Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer
Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Adenocarcinoma of the Rectum, Mucinous Adenocarcinoma of the Colon, Recurrent Colon Cancer, Recurrent Rectal Cancer
- Trial name
- NCT00100841
- Testing
- cetuximab, bevacizumab, oxaliplatin
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer
Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer
PURPOSE: Phase II trial to study the effectiveness of combining capecitabine and irinotecan in treating patients who have locally advanced, recurrent, or metastatic colorectal cancer.
- Trial name
- NCT00022698
- Testing
- Capecitabine, Irinotecan
- Where
- 17 sites in United States
- Volunteers
- 67 people
- Sponsor
- Hoffmann-La Roche
Colorectal Cancer
Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab
RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00588900
- Testing
- cediranib maleate, irinotecan hydrochloride
- Where
- 31 sites in United States
- Volunteers
- 5 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Recurrent Colorectal Carcinoma, Stage IVA Colorectal Cancer
FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer
This phase II trial studies how well fluorouracil, leucovorin calcium, and irinotecan hydrochloride (FOLFIRI) together with panitumumab work in treating patients with colorectal cancer that expresses the RAS and B-Raf…
- Conditions
- Recurrent Colorectal Carcinoma, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer
- Trial name
- NCT02508077
- Testing
- Fluorouracil, Irinotecan Hydrochloride, Laboratory Biomarker Analysis
- Where
- 4 sites in United States
- Volunteers
- 1 people
- Sponsor
- City of Hope Medical Center
Colorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma
Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer
This phase Ib trial studies the side effects and best dose of Hsp90 inhibitor XL888 when given together with pembrolizumab in treating patients with advanced gastrointestinal cancer that has spread to other places in the body.
- Conditions
- Colorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Recurrent Colorectal Carcinoma, Recurrent Pancreatic Carcinoma
- Trial name
- NCT03095781
- Testing
- XL888, Pembrolizumab
- Where
- 3 sites in United States
- Volunteers
- 47 people
- Sponsor
- Emory University
Melanoma, Solid Tumor
Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
This is a Phase 2, multi-center, open-label to evaluate the efficacy and safety of tovorafenib (DAY101) in participants ≥12 years of age with recurrent or progressive melanoma or solid tumors with BRAF fusion or CRAF/RAF1 fusions…
- Conditions
- Melanoma, Solid Tumor, CRAF Gene Amplification, RAF1 Gene Amplification
- Trial name
- NCT04985604
- Testing
- Tovorafenib
- Where
- 20 sites in United States, Australia and 5 more
- Volunteers
- 23 people
- Sponsor
- Day One Biopharmaceuticals, Inc.
Colorectal Cancer
Everolimus in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Previous Therapy
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00390364
- Testing
- everolimus, antiangiogenesis therapy, biopsy
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Rectal Mucinous Adenocarcinoma, Rectal Signet Ring Cell Adenocarcinoma
Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer
This randomized phase III trial is comparing the effectiveness of three adjuvant combination chemotherapy regimens in treating patients who are receiving radiation therapy and fluorouracil either before or after surgery for stage…
- Conditions
- Rectal Mucinous Adenocarcinoma, Rectal Signet Ring Cell Adenocarcinoma, Recurrent Rectal Carcinoma, Stage IIA Rectal Cancer AJCC v7
- Trial name
- NCT00068692
- Testing
- Radiotherapy, Fluorouracil, Leucovorin Calcium
- Where
- United States
- Volunteers
- 225 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Colon Carcinoma, Recurrent Rectal Carcinoma
A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer
This phase II trial studies how well capecitabine and celecoxib with or without radiation therapy works in treating patients with colorectal cancer that is newly diagnosed or has been previously treated with fluorouracil, and has…
- Conditions
- Recurrent Colon Carcinoma, Recurrent Rectal Carcinoma, Stage IVA Colon Cancer, Stage IVA Rectal Cancer
- Trial name
- ADAPT (NCT01729923)
- Testing
- Capecitabine, Celecoxib, Intensity-Modulated Radiation Therapy
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Washington
Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum
Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab
This phase II trial studies how well panitumumab and combination chemotherapy works in treating patients with metastatic colorectal cancer previously treated with combination chemotherapy and bevacizumab.
- Conditions
- Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer
- Trial name
- NCT01814501
- Testing
- panitumumab, irinotecan hydrochloride, fluorouracil
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- John Hays
Colorectal Cancer
Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer
Panitumumab plus bortezomib for colon cancer
- Trial name
- NCT01504477
- Testing
- Panitumumab and bortezomib
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Georgetown University
Microsatellite Unstable Colorectal Cancer, Microsatellite Stable Colorectal Cancer
A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread
The purpose of this study is to examine if Nivolumab by itself, or Nivolumab in combination with other anti-cancer drugs, will result in meaningful tumor size reduction, in participants with colon cancer that has come back or has…
- Conditions
- Microsatellite Unstable Colorectal Cancer, Microsatellite Stable Colorectal Cancer, Mismatch Repair Proficient Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer
- Trial name
- CheckMate142 (NCT02060188)
- Testing
- Ipilimumab, Nivolumab, Cobimetinib
- Where
- 32 sites in United States, Australia and 6 more
- Volunteers
- 385 people
- Sponsor
- Bristol-Myers Squibb
Liver Metastases, Recurrent Colon Cancer
Combination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer
This phase II trial studies how well giving combination chemotherapy and bevacizumab before surgery and radiolabeled monoclonal antibody therapy works in treating liver metastases in patients with metastatic colorectal cancer.
- Conditions
- Liver Metastases, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer
- Trial name
- NCT01320683
- Testing
- oxaliplatin, leucovorin calcium, fluorouracil
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- City of Hope Medical Center
Colorectal Cancer
Surgery With or Without Thalidomide in Treating Patients With Recurrent or Metastatic Colorectal Cancer
RATIONALE: Thalidomide may stop the growth of colorectal cancer by stopping blood flow to the tumor. Giving thalidomide after surgery may kill any remaining tumor cells.
- Trial name
- NCT00019747
- Testing
- thalidomide, adjuvant therapy
- Where
- 6 sites in United States
- Volunteers
- 39 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Metastatic Colorectal Cancer
Radiosensitizing Chemotherapy withSBRT for the Treatment of Inoperable Liver and/or Lung Metastases of CRC
The purpose of this study is to study stereotactic radiotherapy with a dose of 40 Gy in 4 fractions over 2 weeks with concomitant 40 mg/m2 of irinotecan (1st and 3rd irradiation session).
- Trial name
- RSCAMPTO (NCT01220063)
- Testing
- Radiation, Irinotecan
- Where
- 6 sites in France
- Volunteers
- 47 people
- Sponsor
- Institut Cancerologie de l'Ouest